Written by Mark Terry Last week, the Federal Circuit affirmed a D.C. District Court decision extending the patent term of a Wyeth Alzheimer’s drug patent due to U.S. Patent and Trademark Office (USPTO) delay. As a Miami patent lawyer that deals with issued patents often, this case illustrates how a patent holder can use USPTO delays to their advantage by lengthening their patent term accordingly. At the crux of this dispute between Wyeth Pharmaceuticals and the USPTO is a process for calculating the amount that a patent term is adjusted under the American Inventors Protection Act, 35 U.S.C. 154(b).